New hope for rare bleeding disorder: Single-Dose drug trial begins
NCT ID NCT07347249
First seen Jan 21, 2026 · Last updated May 25, 2026 · Updated 16 times
Summary
This study tests a new drug called sutacimig in 18 adults with a rare bleeding disorder (congenital Factor VII deficiency). Participants receive a single dose to see if it is safe and helps control bleeding. The goal is to find a better treatment option for those with severe bleeding history.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL FACTOR VII DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal London Hospital
RECRUITINGLondon, E1 2ES, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.